Is upadacitinib (Rinvoq) safe to use in a patient with elevated creatinine indicating impaired renal function, and how should the dose be adjusted based on estimated glomerular filtration rate (eGFR)?

Upadacitinib Use in Elevated Creatinine

Upadacitinib can be safely used in patients with elevated creatinine, but dose adjustment is required only for severe renal impairment (eGFR 15 to <30 mL/min/1.73m²), and the specific adjustment depends on the indication being treated.

Dose Adjustments Based on Renal Function and Indication

For Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis:

• No dose adjustment needed regardless of severity of renal impairment (mild, moderate, or severe) 1
• Standard dosing of 15 mg once daily applies across all levels of renal function

For Atopic Dermatitis:

• Mild to moderate renal impairment (eGFR ≥30 mL/min/1.73m²): No dose adjustment needed 2, 1
• Severe renal impairment (eGFR 15 to <30 mL/min/1.73m²): Maximum dose 15 mg once daily 2, 1
• End-stage renal disease (eGFR <15 mL/min/1.73m²): Not recommended 1

For Ulcerative Colitis:

• Mild to moderate renal impairment (eGFR ≥30 mL/min/1.73m²): No dose adjustment 1
• Severe renal impairment (eGFR 15 to <30 mL/min/1.73m²): 1
  • Induction: 30 mg once daily for 8 weeks (reduced from standard 45 mg)
  • Maintenance: 15 mg once daily
• End-stage renal disease: Not recommended 1

For Crohn's Disease:

• Mild to moderate renal impairment (eGFR ≥30 mL/min/1.73m²): No dose adjustment 1
• Severe renal impairment (eGFR 15 to <30 mL/min/1.73m²): 1
  • Induction: 30 mg once daily for 12 weeks (reduced from standard 45 mg)
  • Maintenance: 15 mg once daily
• End-stage renal disease: Not recommended 1

Pharmacokinetic Rationale

The limited impact of renal impairment on upadacitinib dosing is supported by pharmacokinetic data showing that renal excretion plays only a minor role in upadacitinib elimination 3. In a dedicated renal impairment study, upadacitinib exposure increased modestly:

• Mild impairment: 18% increase in AUC
• Moderate impairment: 33% increase in AUC
• Severe impairment: 44% increase in AUC 3

These increases are considered clinically manageable, particularly for inflammatory arthritis indications where no dose adjustment is required even in severe impairment 3.

Important Clinical Considerations

Monitor for treatment-related creatinine increases: JAK inhibitors, including upadacitinib, can be associated with increased serum creatinine levels during treatment 2. This requires:

• Baseline renal function assessment before initiating therapy
• Periodic monitoring during treatment
• Distinguishing drug-related creatinine changes from progressive renal disease

Patient selection matters: Patients with comorbid kidney conditions should be carefully selected for JAK inhibitor treatment 2. The 2024 International Eczema Council guidelines emphasize that while upadacitinib can be used in renal impairment, careful patient selection remains important.

Use eGFR, not Cockcroft-Gault: The FDA label specifies dosing based on eGFR (mL/min/1.73m²), not creatinine clearance 1. This aligns with current recommendations to transition away from Cockcroft-Gault equations toward race-free eGFR equations for medication dosing decisions.

Key Pitfall to Avoid

Do not automatically reduce doses in mild-to-moderate renal impairment for rheumatoid arthritis and related inflammatory arthritis conditions—this is unnecessary and may lead to subtherapeutic dosing. The dose adjustments are indication-specific and primarily apply to atopic dermatitis and inflammatory bowel disease when severe renal impairment is present.